Summary

Report Scope
This report provides an in-depth analysis of the global market for radioligand therapeutics (RLT) in cancer treatment. It presents detailed market data for 2024 (base year), estimates for 2025 and forecasts with compound annual growth rates (CAGR) through 2030. The study evaluates current market dynamics, emerging trends and future growth potential driven by the adoption of prostate-specific membrane antigen (PSMA)- and somatostatin receptor (SSTR)-targeted therapies. The report assesses the competitive environment, including product-level analysis of approved radioligand therapies such as 177Lu-vipivotide tetraxetan (Pluvicto) and 177Lu-dotatate (Lutathera), as well as pipeline assets targeting PSMA, SSTR, gastrin]releasing peptide receptor (GRPR) and other tumor-specific receptors. It also examines regulatory pathways and reimbursement frameworks. Market segmentation encompasses product type, indication type, and end user, with additional assessments of drivers, restraints, opportunities, technological advances, and strategic activities such as collaborations, acquisitions, clinical trial investments, and expansion of isotope production capacity. Segmental-level market data (by product type, indication type and end user) is limited to the North America region. This limitation highlights that the market for radioligand therapeutics in cancer treatment is centered in the U.S., where a single companyfs products (Pluvicto and Lutathera from Novartis AG) account for the majority of global sales and where reliable, detailed data are accessible. In other regions, RLT is still in an early stage, with limited commercial adoption and insufficient transparent data to enable detailed segment-level analysis.

Report Includes
- 15 data tables and 57 additional tables
- Overview and an analysis of the global markets for radioligand therapeutics (RLT) in cancer treatment
- Analyses of the global market trends, with historic revenue (sales data) from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030
- Estimates of the current market size and revenue prospects for the global market, along with a corresponding market share analysis based on product type, disease indication, end user and region
- Facts and figures about market dynamics, opportunities and deterrents, technological advances, regulations, prospects and the impact of macroeconomic variables
- Highlights of promising new advancements in precision oncology, the emergence of innovative and effective theranostic agents, applications and potential
- Insights derived from Porterfs Five Forces model, as well as global supply chain analyses
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
- A relevant patent analysis, featuring key granted and published patents
- Analysis of the industry structure, including companiesf market shares and rankings, strategic initiatives, M&A activity and a venture funding outlook
- Profiles of the leading companies, including Novartis AG, ITM Isotope Technologies Munich SE, Telix Pharmaceuticals Ltd., RayzeBio Inc., and Lilly USA LLC.

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Current Market Scenario
Market Dynamics and Growth Factors
Emerging Technologies
Segmental Analysis
Regional Analysis
Conclusion
Chapter 2 Market Overview
Overview
Macroeconomic Factors Analysis
Geographical Factor
Healthcare Spend
Cancer Burden and Demographics
Reimbursement and Funding Climate
Impact of U.S. Tariffs on Radioligand Therapeutics in Cancer Treatment Supply Chains
Porter's Five Forces Analysis
Bargaining Power of Buyers
Bargaining Power of Suppliers
Potential for New Entrants
Threat of Substitutes
Competitiveness in the Industry
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Rising Cancer Incidence and Population Aging
Increasing Approvals and Label Expansions of Radioligand Therapeutics Products
Centers for Medicare and Medicaid Services (CMS) Separate Payment for Therapeutic Radiopharmaceuticals
Market Restraints/Challenges
Therapeutic Isotope Supply Constraints
Nuclear Medicine and Radiopharmacy Workforce Shortage
Growing Competition from Alternative Modalities such as Antibody-Drug Conjugates (ADCs)
Market Opportunities
Development of Alpha-Emitter Therapies and Novel Targets
Earlier-Line Use and Combination Regimens with Standard of Care
Increasing R&D Investments and Strategic Alliances
Chapter 4 Regulatory Landscape
Overview
Regulatory Frameworks by Country/Region
U.S.
Canada
Europe
Emerging Markets
Chapter 5 Emerging Technologies and Developments
Key Takeaways
Targeted Alpha Therapies (TATs)
Next-Generation Isotopes and Smarter Ligands
Personalized, Dosimetry-Guided RLT (AI-Assisted)
Chapter 6 Pipeline and Clinical Analysis
Key Takeaways
Pipeline Analysis
Clinical Trials Analysis
Key Takeaways
Clinical Trial Studies on Radioligand Therapeutics in Cancer Treatment
Chapter 7 Patent Analysis
Key Takeaways
Patent Analysis
Recent Patent Grants
Chapter 8 Market Segmentation Analysis
Segmentation Breakdown
Global Market for Radioligand Therapeutics in Cancer Treatment, by Product Type
Key Takeaways
Lutetium-177 Dotatate
Others (Pipeline)
Global Market for Radioligand Therapeutics in Cancer Treatment, by Indication
Key Takeaways
Prostate Cancer
Neuroendocrine Tumors
Others (Pipeline)
Global Market for Radioligand Therapeutics in Cancer Treatment, by End User
Key Takeaways
Academic/Comprehensive Cancer Centers
Hospital-Based Nuclear Medicine
Specialized Private Nuclear Medicine Clinics
Geographic Breakdown
Global Market for Radioligand Therapeutics in Cancer Treatment, by Region
Key Takeaways
North America
Europe
Emerging Markets
Chapter 9 Competitive Intelligence
Competitive Landscape
Key Takeaways
Novartis AG RLT Sales, 2024
Other Competitors in the Pipeline
Chapter 10 Sustainability in the Global Market for Radioligand Therapeutics in Cancer Treatment: An ESG Perspective
Introduction to ESG
Sustainability in the Global Market for Radioligand Therapeutics in Cancer Treatment
ESG Perspective
Environmental Impact
Social Impact
Governance Impact
ESG Risk Ratings
Conclusion
Chapter 11 Appendix
Methodology
Abbreviations
Sources
Company Profiles
ABDERA THERAPEUTICS
ARICEUM THERAPEUTICS
CLARITY PHARMACEUTICALS
CONVERGENT THERAPEUTICS INC.
CURIUM
FUSION PHARMA
ITM ISOTOPE TECHNOLOGIES MUNICH SE
LILLY USA LLC.
NOVARTIS AG
ORANO MED
PERSPECTIVE THERAPEUTICS
PRECIRIX
RADIOPHARM THERANOSTICS LTD.
RAYZEBIO INC.
TELIX PHARMACEUTICALS LTD.
Few Emerging Companies in the Global Market for Radioligand Therapeutics in Cancer Treatment

ページTOPに戻る

List of Tables/Graphs

List of Tables

Summary Table : Global Market for Radioligand Therapeutics in Cancer Treatment, by Region, Through 2030
Table 1 : Clinical-Commercial Heatmap, by Target and Indication, 2025-2030 Outlook
Table 2 : Healthcare Spending Snapshot and Implications for Radioligand Therapeutics Rollout (Developed versus Emerging Markets)
Table 3 : Reimbursement and Funding Climate, 2024 and 2025
Table 4 : Recent U.S. Regulatory Actions Affecting Radioligand Therapeutics
Table 5 : Selected Clinical Trials Studies on Radioligand Therapeutics in Cancer Treatment
Table 6 : Recent Patents in Radioligand Therapeutics in Cancer Treatment, 2024 and 2025
Table 7 : Global Market for Radioligand Therapeutics in Cancer Treatment, by Product Type, 2022-2024
Table 8 : Global Market for Radioligand Therapeutics in Cancer Treatment, by Indication, 2022-2024
Table 9 : Global Market for Radioligand Therapeutics in Cancer Treatment, by End User, Through 2030
Table 10 : Global Market for Radioligand Therapeutics in Cancer Treatment, by Region, Through 2030
Table 11 : North American Market for Radioligand Therapeutics in Cancer Treatment, by Product Type, Through 2030
Table 12 : North American Market for Radioligand Therapeutics in Cancer Treatment, by Indication, Through 2030
Table 13 : North American Market for Radioligand Therapeutics in Cancer Treatment, by End User, Through 2030
Table 14 : North American Market for Radioligand Therapeutics in Cancer Treatment, by Country, Through 2030
Table 15 : European Market for Radioligand Therapeutics in Cancer Treatment, Through 2030
Table 16 : Emerging Regions' Market for Radioligand Therapeutics in Cancer Treatment, Through 2030
Table 17 : Strategic Initiatives in the Global Market for Radioligand Therapeutics in Cancer Treatment, 2025
Table 18 : Key Focus Areas in ESG Metrics
Table 19 : ESG Rankings for Leading Companies in the Global Market for Radioligand Therapeutics in Cancer Treatment, 2025*
Table 20 : Abbreviations Used in this Report
Table 21 : Report Sources
Table 22 : Abdera Therapeutics: Company Snapshot
Table 23 : Abdera Therapeutics: Product Pipeline
Table 24 : Abdera Therapeutics: News/Key Developments, 2023 and 2024
Table 25 : Ariceum Therapeutics: Company Snapshot
Table 26 : Ariceum Therapeutics: Product Pipeline
Table 27 : Ariceum Therapeutics: News/Key Developments, 2022-2025
Table 28 : Clarity Pharmaceuticals: Company Snapshot
Table 29 : Clarity Pharmaceuticals: Product Pipeline
Table 30 : Clarity Pharmaceuticals: News/Key Developments, 2024 and 2025
Table 31 : Convergent Therapeutics Inc.: Company Snapshot
Table 32 : Convergent Therapeutics Inc.: Product Pipeline
Table 33 : Convergent Therapeutics Inc.: News/Key Developments, 2022-2025
Table 34 : Curium: Company Snapshot
Table 35 : Curium: Product Pipeline
Table 36 : Curium: News/Key Developments, 2024
Table 37 : Fusion Pharma: Company Snapshot
Table 38 : Fusion Pharma: Product Pipeline
Table 39 : Fusion Pharma: News/Key Developments, 2024
Table 40 : ITM Isotope Technologies Munich SE: Company Snapshot
Table 41 : ITM Isotope Technologies Munich SE: Product Pipeline
Table 42 : ITM Isotope Technologies Munich SE: News/Key Developments, 2024 and 2025
Table 43 : Lilly USA LLC.: Company Snapshot
Table 44 : Lilly USA LLC.: Financial Performance, FY 2023 and 2024
Table 45 : Lilly USA LLC.: Product Pipeline
Table 46 : Lilly USA LLC.: News/Key Developments, 2023-2025
Table 47 : Novartis AG: Company Snapshot
Table 48 : Novartis AG: Financial Performance, FY 2023 and 2024
Table 49 : Novartis AG: Product Portfolio
Table 50 : Novartis AG: News/Key Developments, 2023-2024
Table 51 : Orano Med: Company Snapshot
Table 52 : Orano Med: Product Pipeline
Table 53 : Orano Med: News/Key Developments, 2023-2025
Table 54 : Perspective Therapeutics: Company Snapshot
Table 55 : Perspective Therapeutics: Financial Performance, FY 2023 and 2024
Table 56 : Perspective Therapeutics: Product Pipeline
Table 57 : Perspective Therapeutics: News/Key Developments, 2023 and 2024
Table 58 : Precirix: Company Snapshot
Table 59 : Precirix: Product Pipeline
Table 60 : Precirix: News/Key Developments, 2025
Table 61 : Radiopharm Theranostics Ltd.: Company Snapshot
Table 62 : Radiopharm Theranostics Ltd.: Product Pipeline
Table 63 : Radiopharm Theranostics Ltd.: News/Key Developments, 2024 and 2025
Table 64 : RayzeBio Inc.: Company Snapshot
Table 65 : RayzeBio Inc.: Product Pipeline
Table 66 : RayzeBio Inc.: News/Key Developments, 2024
Table 67 : Telix Pharmaceuticals Ltd.: Company Snapshot
Table 68 : Telix Pharmaceuticals Ltd.: Financial Performance, FY 2023 and 2024
Table 69 : Telix Pharmaceuticals Ltd.: Product Pipeline
Table 70 : Telix Pharmaceuticals Ltd.: News/Key Developments, 2024 and 2025
Table 71 : Few Emerging Companies in the Global Market for Radioligand Therapeutics in Cancer Treatment